The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | HORIZON: melflufen & dexamethasone in myeloma
Meral Beksac, MD, of Ankara University, Ankara, Turkey, discusses the results of the HORIZON study (NCT02963493), which investigated melflufen in combination with dexamethasone in the treatment of multiple myeloma in adult patients with disease refractory to pomalidomide and/or an anti-CD38 monoclonal antibody. Furthermore, Dr Beksac discusses the significance of PET as a measure of disease response in this indication as evaluated in the FORTE trial (NCT02203643) presented at EHA 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
